Laboratory Testing Strategies in Wilson’s Disease Diagnosis
Laboratory testing is central to diagnosing Wilson’s disease and differentiating it from other metabolic or liver disorders. Because no single test is definitive, a combination of biochemical markers is typically required to establish an accurate diagnosis.
Serum ceruloplasmin measurement is one of the most commonly used screening tests. Ceruloplasmin is a copper-binding protein produced in the liver, and its levels are often reduced in individuals with Wilson’s disease. However, normal levels do not completely exclude the condition, particularly in early or atypical cases.
Serum copper testing may appear misleading, as total copper levels can be low due to reduced ceruloplasmin. Free copper levels, however, are typically elevated and contribute to tissue toxicity. Interpreting these values requires clinical expertise.
A 24-hour urinary copper excretion test is highly informative. Elevated copper excretion reflects impaired copper metabolism and supports the diagnosis. This test is particularly useful for monitoring treatment response as well.
Liver function tests often reveal abnormalities, including elevated transaminases or signs of chronic liver disease. In some cases, liver biopsy may be performed to directly measure hepatic copper concentration, providing strong diagnostic confirmation.
Laboratory testing forms the foundation of Wilson’s disease diagnosis. When combined with clinical findings and imaging, these tests enable early detection and guide long-term management strategies.